These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 10225112)

  • 1. [Effects of various mutant p53 on the sensitivity of cells to cytostatics].
    Semeniak OIu; Chumakov PM; Kopnin BP
    Biull Eksp Biol Med; 1999 Mar; 127(3):324-7. PubMed ID: 10225112
    [No Abstract]   [Full Text] [Related]  

  • 2. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression.
    Bossi G; Lapi E; Strano S; Rinaldo C; Blandino G; Sacchi A
    Oncogene; 2006 Jan; 25(2):304-9. PubMed ID: 16170357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line.
    Cinti C; Claudio PP; Luca AD; Cuccurese M; Howard CM; D'Esposito M; Paggi MG; Sala DL; Azzoni L; Halazonetis TD; Giordano A; Maraldi NM
    Oncogene; 2000 Oct; 19(44):5098-105. PubMed ID: 11042698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of novel tumour-derived p53 mutations on the transformation of NIH-3T3 cells.
    Donninger H; Binder A; Bohm L; Parker MI
    Biol Chem; 2008 Jan; 389(1):57-67. PubMed ID: 18095870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of p53 in death of IL-3-dependent cells in response to cytotoxic drugs.
    Palacios C; Gutierrez del Arroyo A; Silva A; Collins MK
    Oncogene; 2000 Jul; 19(31):3556-9. PubMed ID: 10918614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug resistance in prostate cancer cell lines is influenced by androgen dependence and p53 status.
    Serafin AM; Akudugu JM; Bohm L
    Urol Res; 2002 Oct; 30(5):289-94. PubMed ID: 12389116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of different mutant p53 transgenes in neuroblastoma cells leads to different cellular responses to genotoxic agents.
    Gangopadhyay S; Jalali F; Reda D; Peacock J; Bristow RG; Benchimol S
    Exp Cell Res; 2002 Apr; 275(1):122-31. PubMed ID: 11925110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Roles of p53 in chemotherapy of glioblastoma].
    Ikeda J
    Hokkaido Igaku Zasshi; 2000 Sep; 75(5):299-314. PubMed ID: 11070791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin.
    Ganjavi H; Gee M; Narendran A; Parkinson N; Krishnamoorthy M; Freedman MH; Malkin D
    Cancer Gene Ther; 2006 Apr; 13(4):415-9. PubMed ID: 16211088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of p53 status on radiation and 5-flourouracil synergy in pancreatic cancer cells.
    Mohiuddin M; Chendil D; Dey S; Alcock RA; Regine W; Mohiuddin M; Ahmed MM
    Anticancer Res; 2002; 22(2A):825-30. PubMed ID: 12014658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity.
    Liu X; Yue P; Khuri FR; Sun SY
    Cancer Res; 2005 Oct; 65(20):9169-75. PubMed ID: 16230375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiosensitization and DNA repair inhibition by pentoxifylline in NIH3T3 p53 transfectants.
    Binder A; Theron T; Donninger H; Parker M; Bohm L
    Int J Radiat Biol; 2002 Nov; 78(11):991-1000. PubMed ID: 12456286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand.
    Naumann U; Kügler S; Wolburg H; Wick W; Rascher G; Schulz JB; Conseiller E; Bähr M; Weller M
    Cancer Res; 2001 Aug; 61(15):5833-42. PubMed ID: 11479223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function.
    de Vries A; Flores ER; Miranda B; Hsieh HM; van Oostrom CT; Sage J; Jacks T
    Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2948-53. PubMed ID: 11867759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced tumor suppression by a p14ARF/p53 bicistronic adenovirus through increased p53 protein translation and stability.
    Huang Y; Tyler T; Saadatmandi N; Lee C; Borgstrom P; Gjerset RA
    Cancer Res; 2003 Jul; 63(13):3646-53. PubMed ID: 12839954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells.
    Baptiste N; Friedlander P; Chen X; Prives C
    Oncogene; 2002 Jan; 21(1):9-21. PubMed ID: 11791172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrovirus vector containing wild type p53 gene and its effect on human glioma cells.
    Hlavatý J; Tyukosova S; Bies J; Hlubinova K; Altaner C
    Neoplasma; 2000; 47(4):204-11. PubMed ID: 11043823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status.
    Bartussek C; Naumann U; Weller M
    Exp Cell Res; 1999 Dec; 253(2):432-9. PubMed ID: 10585266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the Jun kinase pathway blocks DNA repair, enhances p53-mediated apoptosis and promotes gene amplification.
    Gjerset RA; Lebedeva S; Haghighi A; Turla ST; Mercola D
    Cell Growth Differ; 1999 Aug; 10(8):545-54. PubMed ID: 10470854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of cell death sensitivity by mutant p53 in HCV core-expressing cells.
    Cho JW; Park K; Kweon GR; Park JC; Lee JC; Baek WK; Jang BC; Suh SI; Suh MH
    Int J Mol Med; 2005 Mar; 15(3):475-80. PubMed ID: 15702241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.